Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma

Conditions: Renal Cell Carcinoma Interventions: Drug: Tivozanib; Drug: Nivolumab Sponsors: M.D. Anderson Cancer Center; AVEO Pharmaceuticals, Inc. Not yet recruiting

https://clinicaltrials.gov/study/NCT06053658

Source: ClinicalTrials.gov - September 26, 2023 Category: Research Source Type: clinical trials